Ranch Capital Advisors Inc. Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Ranch Capital Advisors Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 66.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,671 shares of the company’s stock after selling 7,233 shares during the quarter. Ranch Capital Advisors Inc.’s holdings in Johnson & Johnson were worth $537,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of JNJ. AE Wealth Management LLC grew its holdings in Johnson & Johnson by 21.7% during the 2nd quarter. AE Wealth Management LLC now owns 321,514 shares of the company’s stock valued at $46,992,000 after buying an additional 57,335 shares in the last quarter. DCF Advisers LLC raised its stake in shares of Johnson & Johnson by 100.0% in the second quarter. DCF Advisers LLC now owns 3,000 shares of the company’s stock valued at $438,000 after acquiring an additional 1,500 shares during the period. Sprucegrove Investment Management Ltd. boosted its position in shares of Johnson & Johnson by 1.2% during the second quarter. Sprucegrove Investment Management Ltd. now owns 109,535 shares of the company’s stock valued at $16,010,000 after buying an additional 1,300 shares during the period. Bridges Investment Management Inc. boosted its holdings in Johnson & Johnson by 74.2% during the 2nd quarter. Bridges Investment Management Inc. now owns 86,997 shares of the company’s stock valued at $12,715,000 after acquiring an additional 37,054 shares during the period. Finally, Godshalk Welsh Capital Management Inc. grew its holdings in shares of Johnson & Johnson by 2.0% in the second quarter. Godshalk Welsh Capital Management Inc. now owns 12,446 shares of the company’s stock worth $1,819,000 after purchasing an additional 240 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. TD Securities cut their price target on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday. Finally, The Goldman Sachs Group dropped their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $164.82 on Friday. The firm has a market cap of $396.67 billion, a PE ratio of 10.28, a P/E/G ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The business has a 50-day moving average price of $161.02 and a 200 day moving average price of $154.17. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.80 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.01%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.